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Brain microvasculature defects and Glut1 deﬁciency
syndrome averted by early repletion of the glucose
transporter-1 protein
Maoxue Tang1,2, Guangping Gao3,4, Carlos B. Rueda2,5,6, Hang Yu7, David N. Thibodeaux7, Tomoyuki Awano1,2,
Kristin M. Engelstad5,6, Maria-Jose Sanchez-Quintero6, Hong Yang5,6, Fanghua Li5,6, Huapeng Li3,4, Qin Su3,4,
Kara E. Shetler5,6, Lynne Jones8, Ryan Seo9, Jonathan McConathy10, Elizabeth M. Hillman7, Jeffrey L. Noebels9,
Darryl C. De Vivo2,5,6 & Umrao R. Monani1,2,6

Haploinsufﬁciency of the SLC2A1 gene and paucity of its translated product, the glucose
transporter-1 (Glut1) protein, disrupt brain function and cause the neurodevelopmental
disorder, Glut1 deﬁciency syndrome (Glut1 DS). There is little to suggest how reduced Glut1
causes cognitive dysfunction and no optimal treatment for Glut1 DS. We used model mice to
demonstrate that low Glut1 protein arrests cerebral angiogenesis, resulting in a profound
diminution of the brain microvasculature without compromising the blood–brain barrier.
Studies to deﬁne the temporal requirements for Glut1 reveal that pre-symptomatic,
AAV9-mediated repletion of the protein averts brain microvasculature defects and prevents
disease, whereas augmenting the protein late, during adulthood, is devoid of beneﬁt. Still,
treatment following symptom onset can be effective; Glut1 repletion in early-symptomatic
mutants that have experienced sustained periods of low brain glucose nevertheless restores
the cerebral microvasculature and ameliorates disease. Timely Glut1 repletion may thus
constitute an effective treatment for Glut1 DS.
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utations in the SLC2A1 gene evolve into the rare but
often incapacitating pediatric neurodevelopmental
disorder, Glut1 deﬁciency syndrome (Glut1 DS)1,2.
Initially considered exceptionally rare, reports that SLC2A1
mutations account for B1% of idiopathic generalized epilepsies
and the recognition of an expanding Glut1 DS phenotype suggest
that there may be in excess of 11,000 individuals afﬂicted with the
disorder in the US alone3,4. Patients with classic Glut1 DS suffer
low brain glucose levels and exhibit a phenotype characterized by
early-onset seizures, delayed development, acquired microcephaly
(decelerating head growth) and a complex movement disorder
combining features of spasticity, ataxia and dystonia5,6. Low
concentration of glucose in the cerebrospinal ﬂuid (CSF), also
known as hypoglycorrhachia, is the most reliable biomarker of
the disease2. The disease characteristics of Glut1 DS are consistent
with the widespread but especially abundant expression of Glut1
in the endothelial cells (ECs) of the brain microvasculature7,
where the protein facilitates the transport of blood glucose across
the blood–brain barrier (BBB) to the CNS.
Although the genetic cause of Glut1 DS was identiﬁed almost
two decades ago and notwithstanding widespread interest in
Glut1 biology, little is known about the precise molecular and
cellular pathology underlying the human disorder. Nor is there an
optimal treatment for Glut1 DS. Clinicians have so far relied
mostly on the ketogenic diet8,9. However, the diet is, at best,
partially effective, mitigating seizure activity in some young
patients but unable to attenuate virtually any other neurological
deﬁcit10.
We modelled Glut1 DS in mice by inactivating one copy of
the murine Slc2a1 gene11. Mutants display many of the signature
features of human Glut1 DS including seizure activity, hypoglycorrhachia, micrencephaly and impaired motor performance.
Here we link overt manifestations of brain dysfunction in the
mutants to profound defects of the cerebral microvasculature. We
demonstrate that low Glut1 protein not only delays brain
angiogenesis but also triggers microvasculature diminution,
without affecting BBB integrity. Repletion of the protein in
neonatal Glut1 DS model mice ensures the proper development
of the brain microvasculature and preserves it during adulthood.
Moreover, seizures and disease progression in these mice is
rapidly arrested. Restoring the protein to 2-week old mutants, in
which certain disease characteristics are readily apparent, is less
effective in shaping normal brain microvasculature. Yet, low brain
glucose levels in the mice are reversed and an overall salutary
effect of the intervention is observed. In contrast, initiating
protein repletion in symptomatic, adult (8-week old) mice raises
brain glucose levels but fails to either mitigate brain
microvasculature defects or attenuate major Glut1 DS disease
features. We conclude that adequate Glut1 protein is indispensable for the proper development and maintenance of the
capillary network of the brain. We further conclude that there is a
limited postnatal window of opportunity to treat Glut1 DS using
Glut1 augmentation as a therapeutic strategy. Nevertheless,
timely reinstatement of the protein proves highly effective in
preventing, indeed reversing, aspects of the disorder in the
symptomatic individual.
Results
Brain microvasculature defects in Glut1 DS model mice. Brain
dysfunction is a characteristic feature of Glut1 DS patients and
model mice. Moreover, the Glut1 protein is abundantly expressed
in endothelia lining the brain microvasculature. We therefore
began our investigation by examining the cerebral capillary
network of mutant and control mice using ﬂuorescently labelled
lectin and an antibody against Glut1. As the structures identiﬁed
2

by the two probes were invariably in perfect register
(Supplementary Fig. 1a), further quantiﬁcation of the microvasculature relied on lectin staining alone. This was carried out
on 2-week, 8-week and 20-week old mice. We began by examining the capillaries in the thalamus, as this region appears
particularly hypometabolic in positron emission tomography
(PET) scans12–14. We found that the density of the capillaries, as
determined by the total length traversed by them within a deﬁned
volume, was no different in mutants and WT mice at 2 weeks of
age (Fig. 1a,b). Nor were there differences in the distribution of
the sizes of individual capillaries or vessel branch points between
the two cohorts of mice (Supplementary Fig. 1b,c). Brain
angiogenesis continued in WT mice over the following eighteen
weeks so that the capillary network had expanded by B27% in
the thalami of 8-week animals and a further B5% by 20 weeks of
age. In striking contrast, the capillary network of 2-week old
Glut1 DS mice not only failed to expand, but rather diminished in
size over the next eighteen weeks, appearing decidedly
fragmented in the end. The microvasculature network in
8-week and 20-week old mutants was thus B30% and
B40% respectively smaller than in age-matched controls
(Fig. 1b). This diminution was not merely a consequence of a
decrease in the overall extent of the capillary network, but
additionally derived from smaller individual lectin-stained vessels
with fewer branches (Fig. 1c,d). To ascertain if the diminished
size of the capillary network in the thalami of mutants applied
more generally to the cerebral microvasculature, we examined
two additional regions—the cortex (primary motor and
somatosensory cortex) and hippocampus (CA1, CA3 and
DG regions)—of the brain. We found that the abundance of
micro-vessels in these regions was similarly reduced in 20-week
old mutants (capillary density: WT cortex ¼ 1,625±36, mutant
cortex ¼ 1,201±32; WT hippocampus ¼ 1,092±44, mutant
hippocampus ¼ 810±30, Po0.001 in each instance, t test,
NZ3 mice of each genotype). Overall, the results suggest that
Glut1 is required both for the elaboration as well as the
maintenance of the cerebral microvasculature.
Diminution of the brain microvasculature could compromise
the integrity of the BBB and lead to extravasation of
serum proteins15,16. To investigate this possibility, we ﬁrst
quantiﬁed serum and CSF concentrations of albumin and
IgG in 5–6 month old Glut1 DS mice and WT littermates. An
increase in the CSF to serum albumin ratio is suggestive
of increased BBB permeability whereas a rise in the CSF index
(ratio of CSF to serum IgG divided by the albumin ratio
in these two compartments – to correct for variances in
BBB permeability) is indicative of enhanced IgG synthesis in
the CNS and possible inﬂammation or infection17,18. We found
no increases in albumin ratio, IgG ratio, or CSF index in the
Glut1 DS mice (Fig. 2a,b; Supplementary Fig. 2a). This argues
against either a disruption of the BBB or CNS inﬂammation in
adult Glut1 DS mutants.
Although there was no signiﬁcant increase in either albumin
or IgG ratio in the mutants, the latter parameter trended higher.
We therefore applied a second method to re-examine
BBB integrity in the mutants. Accordingly, mice were intravenously administered either ﬂuorescently labelled albumin or
IgG, and brain sections examined 16 h later for extravasation of
labelled protein into the parenchyma. In neither experiment was
ﬂuorescence detected in brain parenchyma of mutant mice
(Fig. 2c; Supplementary Fig. 2b). In contrast, and as expected,
pre-treating animals with kainic acid, an excitotoxic agent known
to disrupt the BBB19,20, resulted in copious ﬂuorescent label
outside the brain capillaries (Fig. 2c; Supplementary Fig. 2b). This
suggested once again that Glut1 deﬁciency does not signiﬁcantly
compromise the functional integrity of the BBB.
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Figure 1 | Cerebral microvasculature defects in Glut1 DS. (a) Thalamic sections of Glut1 DS model mice and littermate controls stained with labelled lectin
reveal cerebral angiogenesis defects and diminution of the microvasculature of mutants at 8 and 20 weeks of life. Graphs quantifying (b) aggregate cerebral
capillary length, (c) mean vessel size and (d) average capillary branches in the mutants and controls illustrate the diminished size of the microvasculature
in adult Glut1 DS mice. ***, Po0.001, t-test, nZ9 regions from each of NZ3 mice of each genotype examined.

Recognizing that our experiments may not have detected subtle
alterations in the Glut1 DS BBB, we carried out the following
additional experiments. First, we substituted the albumin and
IgG molecules with the labelled tracer, TMR-biocytin, which,
owing to its much smaller size (B900 daltons) is expected
to traverse a leaky BBB with much greater ease, therefore
enhancing the sensitivity of our assay21. Next, we used our model
mice to examine expression levels of a subset of signature
BBB endothelial genes, perturbations of which are known to
disrupt the BBB22–28. Finally, we investigated CSF levels
of proteins normally restricted to the serum in a cohort of
Glut1 DS patients. Consistent with our earlier ﬁndings, we found
no difference in levels of ﬂuorescently labelled biocytin in the
brain parenchyma of mutant and control animals, whereas
abundant and intense signal was detected in the CNS of mice
treated with the BBB-disrupting agent kainic acid (Supplementary
Fig. 3a). In support of an intact BBB, as assessed by our labelled
tracer assays, we detected no major alterations in the cerebral
expression of Cldn3, Cldn5 and Cldn12 (tight junction proteins),
Abcg2 and Abcb1b (active efﬂux transporters), Cdh5 (adherens
junction protein) and Pvlap (plasmalemma vesicle-associated
protein) (Supplementary Fig. 3b–h). Finally, we found
no evidence of elevated CSF serum proteins and thus
a compromised BBB in Glut1 DS patients evaluated by us
between the ages of 6 months and 10 years (Mean CSF glucose
in mg dl  1: 32.58±0.57, N ¼ 44; Mean CSF lactate in mmol l  1:
0.93±0.03, N ¼ 44; Mean CSF protein concentration in mg dl  1:

20.52±1.10 versus 22±5 (ref. 29) P ¼ 0.19, one sample t test,
N ¼ 44 and N ¼ 599 respectively). We conclude that although
there is a distinct loss of the brain microvasculature in adult
Glut1 DS mice, the BBB in these animals and likely in human
patients remains largely intact.
Although our results clearly demonstrate that Glut1 deﬁciency
results in a poorly developed brain microvasculature, how this
evolves is unclear. Accordingly, in a concluding set of analyses, we
sought to explore potential mechanisms linking Glut1 to the
process of angiogenesis. Two results appear to establish such
a link. First, we discovered a sharp decline in levels of Vegfr2
in 2-week old Glut1 DS mutants. Transcripts as well as protein
were diminished in expression. Importantly, the relative paucity
of the molecule was restricted to blood vessels, remaining
unchanged in the capillary-depleted fraction (parenchyma) of
the mutant brain (Fig. 3a–c). Vegfr2 is a major positive-signal
transducer expressed in ECs as capillaries form and expand,
establishing it as a potential mediator of the microvasculature
defects in Glut1 DS30,31. We also investigated the effects of Glut1
deﬁciency on glycolytic ﬂux, a modest inhibition of which is
known to perturb blood vessel formation32,33. To do so, we used
astrocytic cells from Glut1 DS mutant mice and WT controls to
assess rates of extracellular acidiﬁcation (ECAR) and oxygen
consumption (OCR), measures of glycolytic ﬂux and
mitochondrial respiration respectively34. Both basal glycolytic
ﬂux and maximum respiratory capacity declined signiﬁcantly in
mutant cells (Fig. 3d; Supplementary Fig. 4a,b). This suggests that
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Figure 2 | An intact blood–brain barrier in Glut1 DS model mice. Evaluation of (a) CSF:Serum IgG and albumin ratios and (b) CSF index fails to provide
evidence of any extravasation of serum proteins into the CSF of adult Glut1 DS mutant mice. P40.05, t-test, NZ4 mice of each genotype. (c) Labelled
IgG systemically administered into Glut1 DS mutants does not escape into the neuropil. Note green ﬂuorescence outside the microvasculature following
chemically induced disruption of the BBB.

Glut1 haploinsufﬁciency does indeed impact glycolysis and
lactate release, establishing a second potential link between
Glut1 paucity and a diminished microvasculature.
Glucose uptake restored in patient cells induced to express Glut1.
To determine if Glut1 repletion reverses or halts brain microvasculature defects and to explore the feasibility of this approach
as a broader strategy to treat Glut1 DS, we sought to deliver
and restore the protein to mutant mice. Adeno-associated virus
9 (AAV9) has emerged as an efﬁcient vector to deliver therapeutic
genes to target tissues35–39. Accordingly, we resolved to exploit
AAV9 as a therapeutic vector. First, we investigated our
constructs in vitro in ﬁbroblasts from a Glut1 DS patient found
to express low Glut1 protein. Murine (mGlut1) as well as human
Glut1 (hGlut1) expression constructs were prepared by cloning
the respective cDNAs into recombinant AAV plasmids harboring
a chicken b-actin promoter element. Glut1 DS ﬁbroblasts were
then transfected with mGlut1, hGlut1 or an eGFP-containing
construct. Each of the Glut1 constructs but not eGFP increased
4

Glut1 levels in the ﬁbroblasts (Fig. 3e; Supplementary Fig. 5a).
To determine if the construct-derived Glut1 was functional,
we subjected ﬁbroblasts co-transfected with one or the other
Glut1 construct and an eGFP plasmid to a glucose uptake
assay40,41. Uptake of 2-deoxyglucose (2-DOG), a labelled glucose
analog, was indeed enhanced by the Glut1 constructs,
approaching levels in control cells (Fig. 3f; Supplementary
Fig. 5b). This suggested that the proteins produced from the
constructs were functional.
Phenotypic rescue following early Glut1 repletion. Having
demonstrated the functionality of the Glut1 constructs in vitro,
we proceeded to test the effect of restoring protein in model mice.
For this, we selected the mGlut1 construct. As a prelude to this
and our later experiments, we examined the distribution of
an AAV9-eGFP construct following systemic administration
of the virus into postnatal day 3 (PND3) Glut1 DS mice.
As expected, eGFP ﬂuorescence was found in all major organ
systems at 1-month. Importantly, this included the brain
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Figure 3 | Potential mediators of angiogenesis defects in Glut1 DS and a functional evaluation of Glut1 constructs for gene replacement.
(a) A quantiﬁcation of Vegfr2 RNA levels demonstrates reduced transcripts speciﬁcally in the capillaries of the Glut1 DS brain. (b) Western blot analysis
and (c) a quantiﬁcation of Vegfr2 protein in the capillaries (Cap) and the capillary-depleted brain (CDB) fraction also depict reduced protein in mutant brain
vessels. Also shown in the blot are corresponding Glut1 levels which are particularly high in the capillaries (55 kDa isoform) compared with the
CDB fraction (45 kDa isoform). Results of high as well as low exposure times are depicted. (d) Basal glycolytic ﬂux and maximal respiration are both
signiﬁcantly compromised in cells from Glut1 DS model mice. Panels a–d: *, **, Po0.05, Po0.01, t-test, NZ3 samples, 2 independent preparations.
(e) Western blot depicting an increase in Glut1 protein following transfection of Glut1 DS patient ﬁbroblasts with either a murine (lane 2) or human (lane 3)
Glut1 cDNA construct. The ubiquitously expressed SMN protein was used as a loading control. (f) Quantitative representation of the levels of a radiolabelled glucose analogue, 2-DOG, taken up by cells transfected with the Glut1 constructs. Note the increase in the labelled 2-DOG in cells that were
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ANOVA.

microvasculature (Supplementary Fig. 6a). Accordingly, we
next administered a cohort of PND3 Glut1 DS mice either
4.2  1011 GC of AAV9-Glut1 or vehicle alone. Wild-type mice
administered vehicle alone served as controls. Six to eight weeks
later, motor performance was examined. As expected from
previous work11, mutants treated with vehicle alone performed
very poorly on a rotarod relative to WT littermates. In
contrast, AAV9-Glut1-treated mutants exhibited a dramatic
improvement—at all time points tested (Fig. 4a). In a second
assay for motor performance, the vertical pole test, the Glut1treated mutants performed as proﬁciently as WT mice (Fig. 4b).
Mutants administered AAV9-Glut1 through a different route—
into the intracerebral ventricles—also displayed improved motor
performance, whereas no additional beneﬁt accrued from overexpressing Glut1 in WT mice (Supplementary Fig. 6b). Unless
otherwise noted, subsequent results stem from systemically
administered virus.
To determine if the improved motor performance of the
AAV9-Glut1-treated mutants was a consequence of increased
Glut1 expression, we quantiﬁed the transcript as well as the
protein in brain tissue of 20-week old mice. This time point also

marked a period, in mutants as well as wild-type animals, during
which Glut1 mRNA levels stabilized (Supplementary Fig. 6c).
QPCR experiments demonstrated that Glut1 transcripts were
indeed increased in the treated mice, either approaching or, in
some instances, exceeding levels in WT littermates (Fig. 4c).
Expression of Glut1 also increased in other tissues of AAV9Glut1-treated mice (Supplementary Fig. 6d–g). Western blot
analysis of Glut1 protein in brain tissue reﬂected the results of
the QPCR experiments (Fig. 4d,e), and further demonstrated
that the repletion experiments resulted in concomitant increases
in both astrocytic (45 kDa) as well as endothelial (55 kDa)
isoforms of the Glut1 protein. These results provide a molecular
basis to the mitigation of the motor defects observed in treated
model mice.
To determine whether early repletion of Glut1 had rescued or
prevented hypoglycorrhachia and micrencephaly, CSF glucose
and brain weight respectively were examined at 20-weeks in
virus-treated mice and relevant controls. As a prelude to these
experiments and to obtain baseline values for subsequent
analyses, we measured blood and CSF glucose levels as well as
brain and body weights periodically between 1 week and 20 weeks
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Po0.01, Po0.001 respectively, one-way ANOVA for each panel in the ﬁgure.

in naive mutant and WT animals. Whereas blood glucose levels
did not differ signiﬁcantly in mutants at any of the time points
chosen for evaluation, CSF glucose levels in the animals were
dramatically reduced as early as 1 week of age (Supplementary
Fig. 7a,b). Moreover, in contrast to CSF glucose concentrations in
WT mice which peaked at B3 weeks of age, remaining steady
thereafter for the remainder of the evaluation period, levels in
mutants declined signiﬁcantly between 3 and 20 weeks of
age (Supplementary Fig. 7b). This trend was reﬂected in
CSF:blood glucose values (Supplementary Fig. 7c), consistent
with a diminution of the brain microvasculature following the
period of weaning and suggestive of an exacerbation of Glut1
DS with age. Overall body weight of mutant mice mirrored that
of WT littermates over the period of assessment (Supplementary
Fig. 7d). In contrast, a signiﬁcant reduction in brain weight was
detected in the Glut1 DS mice as early as 2 weeks of age
6

(Supplementary Fig. 7e). This difference persisted into adulthood.
Collectively, the results reveal a lag between discernible
hypoglycorrhachia and the appearance of micrencephaly,
suggesting that Glut1 paucity and, consequently, reduced cerebral
glucose conspire to retard the development of the brain relatively
early in postnatal life.
Having determined the evolution of hypoglycorrhachia
and micrencephaly in untreated mutants, we assessed these
parameters in mutants administered AAV9-Glut1. CSF glucose
levels in these mice had increased by B64% relative to those in
age-matched vehicle-treated mutants, while the CSF:blood
glucose ratio, a more physiologically relevant parameter had
risen even further by B76%, approaching B80% of WT values
(Fig. 4f,g). Furthermore, and consistent with changes in brain
weight lagging reductions in CSF glucose, micrencephaly in
the treated mutants had either been prevented from developing
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and/or completely reversed (Fig. 4h). A similar mitigation of
these parameters was observed in mutants treated via the
intracerebral ventricles (Supplementary Fig. 7f–h). Importantly,
mice systemically administered AAV9-eGFP did not differ with
respect to these two parameters from vehicle-treated animals,
ruling out the possibility of a therapeutic effect of virus alone
(Supplementary Fig. 7f–h). Together, these results attest to the
marked therapeutic effect of early Glut1 repletion on disease.
Early Glut1 repletion normalizes microvessels and reduces
seizures. Glut1 DS impairs brain glucose uptake11–13.
Accordingly, we next ascertained if restoring Glut1 to mutant
mice had reversed this impairment. Mutants treated with AAV9Glut1 virus at PND3 and relevant controls underwent dynamic
PET imaging at 12 weeks of age after the intravenous
administration of 200–235 mCi of [18F] ﬂuorodeoxyglucose
(FDG), a glucose analogue widely used for clinical imaging.
As expected, radioactive signal in brain tissue of anesthetized,
vehicle-treated mutants was signiﬁcantly lower than that in brains
of WT mice, a ﬁnding congruent with decreased metabolism in
the brain parenchyma of Glut1 DS mice (Fig. 5a). In contrast,
signal in brain tissue of AAV9-Glut1 mice was enhanced and
restored to levels seen in WT mice (Fig. 5a,b). This result is
consistent with the outcome of our other experiments and
suggests that early repletion of Glut1 protein prevents or may
indeed rescue an impaired ability of the Glut1 DS organism to
transport blood glucose into the cerebral parenchyma.
Finally, we asked if early Glut1 repletion had allowed
for proper brain angiogenesis, had ensured the maintenance of
the normal cerebral microvasculature and had prevented the
onset of epileptic seizure-like activity characteristic of Glut1 DS.
To address the ﬁrst question we examined the capillary network
in the brains (thalamus, cortex and hippocampus) of
AAV9-Glut1-treated mice and controls at 20 weeks of age.
Coronal sections stained with ﬂuorescently labelled lectin showed
that the architecture of the capillary network in the brains
of AAV9-Glut1-treated mice was much more intricate than
that of vehicle-treated mutants, indeed as elaborate as that of
WT mice (Fig. 5c). When we quantiﬁed the capillaries in
the different brain regions of the three groups of mice we were
able to demonstrate that microvasculature density in the AAV9Glut1-treated mice was indeed equivalent to that of WT mice
and, expectedly, greater than that of their untreated cohorts
(Fig. 5d). To conﬁrm that the observations that we had made
of the microvasculature in ﬁxed tissue applied to normally
perfused vessels as well, we resorted to an in vivo imaging
technique that enabled us to assess the brain capillary network in
live mice42. Following administration of labelled dextran into the
tail veins of the mice, we exploited 2-photon microscopy to
examine vessels within the somatosensory cortex of the three
cohorts of animals. In accordance with earlier results, we found
that whereas a signiﬁcant diminution of the capillary network
appeared in vehicle-treated Glut1 DS mutants, the size and
complexity of the network was restored in mutants administered
the AAV9-Glut1 vector (Fig. 5c,e,f; Supplementary Movies 1–3).
We concluded our analysis of the effects of early Glut1 repletion
by assessing brain activity in the three cohorts of mice. Glut1
deﬁciency triggers epileptic seizure-like activity as assessed by
electro-encephalograms (EEGs)11,14. This defect was also
mitigated by early Glut1 repletion. Thus, whereas vehicletreated mutants continued to exhibit frequent seizures, Glut1treated model mice were either seizure-free or experienced far
fewer abnormal EEG events (Supplementary Fig. 7i,j).
Since these pre-clinical studies could serve as a springboard for
the treatment of human Glut1 DS, we were interested in

determining if Glut1 repletion triggered any deleterious
effects in the major organ systems of the body. We furthermore
investigated if expression of the virally delivered Glut1 transgene
was sustained over time. A histochemical analysis of the
major organ systems of the treated mutants stained with
hematoxylin/eosin showed that except for subtle evidence of
centrolobular steatosis in the liver, cellular morphology appeared
grossly normal (Supplementary Fig. 8a). The steatosis likely
derives from high expression of construct-derived Glut1 in the
liver, transport of blood glucose into this organ and eventual
conversion of the glucose to lipids. QPCR experiments
to examine Glut1 expression longitudinally in neonatally treated
mutants indicated sustained and robust expression of
the transgene as late as 8 months of age (Supplementary
Fig. 8b), suggestive of relatively low turnover of brain
cells transduced by the virus and therefore a limited requirement
for repeated administration of the therapeutic virus. In
aggregate, our results indicate that Glut1 DS model mice, treated
as neonates with AAV9-Glut1, recover and/or are prevented
from becoming fully symptomatic. Early repletion of the
Glut1 protein may therefore have a similar outcome in human
Glut1 DS patients.
A restricted therapeutic window in Glut1 DS model mice.
Considering the therapeutic effects of early Glut1 repletion
and the need to treat the symptomatic individual, we resolved to
use our model mice to attempt to deﬁne the temporal requirements for Glut1. Accordingly, we selected two additional time
points to restore the protein. The ﬁrst—2 weeks of age—was
chosen as it is the start of the period when mice rapidly transition
from a high-fat (B30%; ketogenic) diet43 derived exclusively
from milk to a solid diet which comprises greater levels (455%)
of carbohydrates and relatively little (5–9%) fat44. Coincidentally,
this marks the beginning of a signiﬁcant decline in the expression
of the Mct1 gene45,46, a concomitant increase in Glut1
expression7 and initial evidence of retarded brain growth in our
mutants. The second time point—8 weeks of age—marks a period
during which Glut1 DS mutants are fully symptomatic. Mutants,
at each of these time points were systemically administered
AAV9-Glut1. The outcome was tested by ﬁrst examining motor
performance on the rotarod. To enable meaningful comparisons
to mutants in which Glut1 repletion had been effected at PND3,
testing was performed at identical time points. Interestingly, we
found that mutants treated at 2 weeks of age performed
signiﬁcantly better than their vehicle-treated counterparts at all
time points examined (Fig. 6a). In fact, between 8 weeks
(PND3-treated: 857 s±31 s; 2-wk-treated: 868 s±35 s; nZ15,
P ¼ 0.8; t-test) and 12 weeks (PND3-treated: 851 s±28 s;
2-wk-treated: 792 s±46 s; nZ15, P ¼ 0.28; t-test) of age, they
performed as well as mutants treated at PND3. In marked
contrast, restoring Glut1 at 8 weeks of age bestowed no signiﬁcant
beneﬁt at any time point to the mutants (Fig. 6a). This result
provides initial evidence of a limited therapeutic window of
opportunity to restore Glut1 as a means of treating Glut1 DS.
To ensure that poor motor performance in mice treated at
8 weeks was not merely a consequence of poor transduction
efﬁciency and thus poor expression caused by introducing the
virus during adulthood, we assessed Glut1 mRNA and protein
levels in brain tissue of the mice at 20 weeks of age. Expression in
animals treated at 2 weeks was similarly examined. We found that
Glut1 expression in the two cohorts of mutants was signiﬁcantly
greater than that in vehicle-treated mutants and at least as high as
that in WT controls (Fig. 6b–d), suggesting that low transgene
expression is unlikely to explain the poor outcome in mutants
treated at 8 weeks.
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Figure 5 | Normal cerebral microvasculature and brain glucose uptake in mutants treated early with AAV9-Glut1. (a) Representative coronal images of
small PET scans at 3–6 min following administration of 18F-FDG, show reduced uptake in the brain of a mutant mouse relative to WT and mutant mice
treated with AAV9-Glut1. (b) Mean brain standardized uptake values (SUVs) at 3–6 min after injection of 18F-FDG in WT controls (SUV ¼ 2.2±0.11) and
mutants treated with either vehicle (SUV ¼ 1.8±0.04) or AAV9-Glut1 (SUV ¼ 2.1±0.15). **, Po0.01, one-way ANOVA, NZ4 mice in each cohort.
(c) Immunohistochemistry or live-imaging experimental results of the brain microvasculature of model mice administered AAV9-Glut1 depicts a capillary
network that is as elaborate and dense as that of WT, control littermates. Note reduced density and fragmented aspect of the brain capillaries in all three
brain regions of vehicle-treated mutants. Also note (lower panels) the fewer FITC-Dextran perfused vessels in vehicle-treated but not AAV9-Glut1-treated
model mice. Graphical representations of cerebral capillary densities of the three groups of mice following an analysis of (d) 4% PFA ﬁxed tissue or
(e,f) 2-photon live-imaging experiments. ***, Po0.001, one-way ANOVA, nZ9 regions from each of NZ3 mice of each cohort.

To further analyse mutants administered virus at the two later
time points, we assessed the effects of Glut1 repletion on
CSF glucose levels and brain size at 20 weeks of age. We found
that CSF glucose concentrations only increased appreciably in
mice treated at 2 weeks of age (Fig. 6e). However, interestingly,
CSF:blood glucose ratios increased in both cohorts of mice,
a consequence of lowered blood glucose concentrations (Fig. 6f).
The drop in blood glucose was also noted, albeit to a lesser extent,
in mice treated at PND3 (Fig. 4f). Considering that the
8

measurements were made in fasting animals, one possible
explanation of this outcome is that systemic expression of virus
predisposes the animals, when fasted, to hypoglycemia—a likely
result of high expression of the Glut1 transgene in organs such
as liver and muscle where it contributes to elevated glucose
uptake thus lowering serum glucose concentrations. Indeed,
blood glucose concentrations in non-fasting mice treated
with virus at PND3 or 2 weeks appeared no different from those
in controls (Supplementary Fig. 9). Notwithstanding these
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ﬁndings, the aggregate results suggest that even late repletion of
Glut1 protein is capable of raising CSF glucose levels relative to
those in the blood.
When we examined the effects of restoring Glut1 on the
micrencephalic Glut1 DS phenotype, we found that the brains of
2-week-treated mutants were signiﬁcantly larger than those of
vehicle-treated mice (Fig. 6g). This was even more evident when
brain:body weight ratios were compared. In fact, corrected mean
brain weight in mutants now appeared no different from that of
WT mice (Fig. 6g). Given the obvious difference in this parameter
between mutants and WT mice when virus was initially
administered—at 2 weeks, the inability to detect it at 20 weeks
suggests that the micrencephalic phenotype is reversible if Glut1
is restored in a timely manner. In contrast to the result in mice
treated at two weeks, the micrencephaly persisted in the mice
treated at 8 weeks. This suggests that even if relative CSF glucose
concentrations are augmented by restoring Glut1 at this advanced
stage of the disease, stimulating the expression of the protein fails
to halt or reverse effects on brain volume.
Earlier Glut1 repletion results in a more extensive capillary
network. To conclude our analysis of mutants treated at 2 and
8 weeks respectively, we assessed the effects of the treatment on
the brain microvasculature at 20 weeks of age. Consistent with the
persistence of an overt motor phenotype and reduced cerebral

volume in mice treated at 8 weeks, the microvasculature within
the brains of the mutants appeared fragmented, less dense and
greatly reduced in complexity relative to that of WT controls
(Fig. 7a). In fact, qualitatively, it looked no different from that of
age-matched, vehicle-treated mutants. Quantiﬁcation of the
density of the capillaries, the average size of the individually
stained blood vessels and the frequency with which the capillaries
branched respectively conﬁrmed this to be the case (Fig. 7b–d). In
contrast, and congruent with other parameters in the mutants,
the brain microvasculature of mice treated at 2 weeks was signiﬁcantly more elaborate than that of vehicle-treated or 8-weektreated mutants but less so than that of WT mice or mutants
treated at PND3 (Fig. 7a,b). We noted similar differences when
we quantiﬁed the average sizes of the capillaries and the number
of occasions on which they branched except that the mean values
obtained from mice treated at 2 weeks were statistically equivalent
to those of PND3-treated and WT mice. Still, these results once
again link Glut1 DS to brain microvasculature defects and
demonstrate a marked correlation between the timing of Glut1
repletion, the ability to restore the cerebral capillary network and
overall therapeutic effect realized by the mutant organism.
Discussion
Although the genetic cause of Glut1 DS was revealed almost two
decades ago, relatively little progress has been made in identifying

NATURE COMMUNICATIONS | 8:14152 | DOI: 10.1038/ncomms14152 | www.nature.com/naturecommunications

9

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14152

a
Mutant (PND3) + AAV9-Glut1

Mutant (2 wk) + AAV9-Glut1

Mutant (8 wk) + AAV9-Glut1

Mutant (PND3) + vehicle

Lectin

Wild type

25 μm

c
NS
1,500

***
NS

1,000
500
0

d
100

***
Average vessel size (μm)

Brain capillary density
(aggregate length in
μm per unit volume)

2,000

NS

80
60

***

15

***

NS

40
20
0

NS
Number of vessel
branch points

b

10
NS
5

Mut + vehicle
Mut (PND3) + AAV9-Glut1
Mut (2wk) + AAV9-Glut1
Mut (8wk) + AAV9-Glut1
Wild type

0

Figure 7 | Brain capillary network restored following early but not late repletion of the Glut1 protein. (a) Representative immuno-histochemical
photomicrographs of the thalamic microvasculature in relevant controls and mutants treated with AAV9-Glut1 at various stages of the disease.
Note persistent fragmentation and reduced complexity of the capillary network in vehicle-treated mutants and mutants treated at 8 weeks of age,
an intermediate capillary density in cohorts treated at 2 weeks of age and a relatively normal microvasculature in mice administered virus at PND3.
Quantitative estimation of (b) aggregate cerebral capillary length, (c) mean vessel length and (d) number of branches per capillary in the different cohorts
of mice. ***, Po0.001, one-way ANOVA, nZ9 regions from NZ3 mice in each cohort examined.

a truly effective treatment for the disorder, and much remains
to be learned about the cellular pathology linking Glut1
mutations to the characteristic brain dysfunction seen in patients.
Here, we attempted to address these deﬁciencies in model mice.
Three principal ﬁndings emerge from our study. The ﬁrst
highlights novel defects of the brain microvasculature in the
Glut1 deﬁcient organism. These involve both a delay in the initial
expansion of the cerebral capillary network as well as a later
impairment in its maintenance. Thus in mature mutants,
a striking diminution of the capillary network became evident.
Remarkably, though, no discernible alteration in BBB integrity
was noted. Our second salient ﬁnding demonstrates that gene
replacement using an AAV9 vector constitutes a relatively
straightforward, safe and highly effective means of treating
Glut1 DS. Glut1 repletion in neonates had a major therapeutic
effect on mutant mice, arresting the onset of a motor phenotype,
enabling the development of the brain microvasculature and
restoring parameters typically perturbed in the mutant to the
wild-type state. Our ﬁnal notable result addresses the temporal
requirement for the Glut1 protein and allows one to deﬁne
a window of opportunity to treat Glut1 DS by means of restoring
the protein. Initiating a treatment in juvenile animals that were at
least partially symptomatic, reversed hypoglycorrhachia,
improved motor performance, accelerated the growth of the
brain and facilitated the expansion of the cerebral microvasculature. Akin to effecting repletion during neonatal and early
postnatal life, restoring the protein to the fully symptomatic
adult mutant raised characteristically low brain glucose levels.
However, in contrast to the outcome of early repletion,
augmenting the Glut1 protein late failed to mitigate any other
major feature of the Glut1 DS phenotype. We suggest that the
accumulating damage sustained by the Glut1 deﬁcient brain as it
attempts to establish and reﬁne important neural circuits
eventually precludes the possibility of therapeutic rescue even if
overall cerebral Glut1 expression is eventually restored. Our
results predict that Glut1-deﬁcient patients will be most
responsive to gene replacement-type treatments relatively early
10

in the course of the disease. Nevertheless, there exists a
period during the symptomatic phase of the disease when Glut1
DS can be effectively treated. These ﬁndings argue for the use
of new-born screens to identify the pre-symptomatic Glut1
DS patient.
Although widely expressed, Glut1 is particularly abundant in
the ECs of the brain microvasculature47. Moreover, brain
dysfunction is a signature feature of Glut1 DS. Examining the
capillary network of our mutant mice therefore appeared to
be logical way to initiate our investigation. Still, we were startled
by how profoundly loss of one copy of the Slc2a1 gene
had affected the elaboration of the brain microvasculature.
Myriad genes govern CNS angiogenesis (ref. 48 and references
therein), but few trigger such marked defects without a total
ablation of their activities. Interestingly, the diminution of the
brain capillary network that we observed became evident only in
mature mice and did not compromise BBB integrity. The ﬁrst
ﬁnding—that of angiogenesis defects—is consistent with those of
two prior reports, in which Glut1 deﬁcient model ﬁsh and mice
respectively were studied49,50. The second—defects of
barriergenesis—is not. While the distinct ﬁndings in Glut1
deﬁcient ﬁsh has a logical explanation and likely stems from a
much greater (B90% versus B50% in our study) level of Glut1
knockdown49, the report of Winkler et al.50 is more curious and
difﬁcult to reconcile with ours. In their study, massive (410-fold)
extravasation of serum proteins was observed as early as 2 weeks.
Cerebral vasogenic edema ought to have followed but,
surprisingly, was not reported. More importantly, such edema
has neither been cited in the literature as characteristic of
Glut1 DS patients nor detected by us over a three decade period
in the clinic. These clinical observations correlate to a greater
extent with our ﬁndings of an intact BBB in model mice than
they do with those of Winkler and colleagues. Still, one
oft-overlooked but important factor that might explain the
distinct ﬁndings in the study of Winkler et al. is a difference in
mouse strain background. Whereas our mice were maintained on
a pure 129/SvJ background, the mutants in the study by Winkler
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Figure 8 | Relationship between brain microvasculature defects and Glut1 deﬁciency. A model illustrating the direct as well as indirect effects of reduced
Glut1 protein on brain microvascular ECs and the consequences of such a reduction ﬁrst, on the capillary network and then on brain circuitry. Note that the
BBB remains intact in the absence of overt cell loss and that ECs express 20–30 times more Glut1 than do astrocytes.

et al. derived from a mixed 129/SvJ-C57Bl/6J strain background.
Genetic strain background is known to have profound effects
on the disease phenotypes of model mice51,52. It is possible
that strain-derived modiﬁers on the pure 129/SvJ background
underlie the less severe BBB phenotype we report here. Testing
this hypothesis will require additional studies.
The simultaneous existence of an intact BBB such as the one
we report in our mutants and a simpliﬁed microvasculature
appears puzzling at ﬁrst, but is not necessarily surprising.
Endothelial cells, particularly those at the leading edges of vessel
sprouts (tip and stalk cells) so essential to the expansion of
the microvasculature network, are known to be highly sensitive
to metabolic or genetic perturbations33,53. For instance,
perturbing Notch signalling or knocking down PFKFB3
profoundly affects the development of the microvasculature
by potently inhibiting tip cell activity. Yet, ECs that constitute
vessels that have already formed are relatively unaffected.
Such phalanx cells merely enter a state of quiescence, exhibiting
little evidence of ER, oxidative or energy stress and thus few signs
of actual degeneration33. Accordingly, one might not expect
the structural (BBB) integrity of the cells to be affected.
Glut1 mutations could similarly perturb the activity of
endothelial tip and stalk cells, becoming especially detrimental

to their ability to pioneer new vessels and expand the capillary
network in response to the demands of a maturing
brain. This chain of events involving both a proliferation
(BPND0 to BPND15) as well as expansion (BPND10 to
PND25) of ECs54 is encapsulated, in part, in a model depicted
in Fig. 8, although the precise insult(s) to neuronal circuitry
remain(s) to be identiﬁed. It is to be noted that in addition to
cell-autonomous perturbations within the ECs, it is likely that
non-cell autonomous perturbations—originating in astrocytes
and/or pericytes—impact the former, eventually hindering
angiogenesis. One appealing, astrocyte-derived mediator is
lactate, decreased levels of which have been shown to inhibit
EC proliferation and vessel formation55.
Our gene repletion studies and the identiﬁcation of
a therapeutic window of opportunity begin to deﬁne the temporal
requirements for the Glut1 protein. Early restoration was clearly
most effective but repletion at PND14 also had a marked effect.
Subsequent augmentation, once the brain is considered mature,
failed to provide beneﬁt. These results are a logical outcome for
a protein whose primary cellular site of action in ensuring proper
brain development is assumed to be the cerebral microvasculature. These results are also a reﬂection of the normal postnatal
development of the brain capillary network. In rodents, this
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involves a proliferation of ECs that peaks at BPND10 and
subsides by BPND15 (ref. 54). Subsequent increase in the size
and complexity of the network, which eventually abates by
1 month, is mainly through the sprouting and elongation
of existing cells. The expansion of the network coincides with
an increase in expression of microvascular Glut1. Partial rescue
of the Glut1 DS phenotype following gene replacement at PND14
is therefore expected and consistent with our ﬁndings. The
maturation of the brain microvasculature is largely complete by
B1 month54, likely reﬂecting the establishment of the adult
complement of brain circuits. Interestingly, total cerebral Glut1
expression exhibits a decline during this period (Supplementary
Fig. 7c). In this respect the requirements for Glut1 are not
dissimilar to those of SMN, another widely expressed protein that
is especially important in neuromuscular junction maturation
and whose deﬁciency causes the motor neuron disease, spinal
muscular atrophy56,57. Depleting SMN following neuromuscular
junction maturation has a relatively benign effect57. Given
the relative stability of the adult brain microvasculature, it
would not be surprising if depleting Glut1 once the network is
established is as innocuous.
This study has addressed important basic as well as clinically
relevant aspects of Glut1 biology. However, as is often the case,
it also raises interesting questions. For instance, what links
reduced Glut1 to brain microvasculature defects? Plausible
connections that have emerged from this study and will have to
be pursued include reduced glycolytic ﬂux and/or glycolytic
intermediates, genes downstream of Glut1, for example, Vegfr2,
or some combination thereof. Second, how do low Glut1 and a
diminution of the cerebral capillary network lead to brain
dysfunction? Micrencephaly is a well-established disease characteristic, but whether this is a consequence of overt cell loss,
lower synaptic density or both, remains to be determined. In
parallel, identifying speciﬁc regions of the brain that are affected
will shed important light on the spatial requirements for cerebral
Glut1. Finally, in spite of our observations of a grossly intact
BBB in the Glut1 deﬁcient organism, does protein haploinsufﬁciency trigger subtle, size-selective loosening of the barrier as
reported in mice deﬁcient in Cldn5? Notwithstanding these and
other important questions raised here, our results serve as an
important step in the quest to effectively treat Glut1 DS.
Methods
Primary cell culture experiments. Before testing the efﬁcacy of the Glut1
constructs in model mice, they were assessed in patient ﬁbroblasts. To do so,
1  106 cells, derived from skin biopsies from patients or controls seen at the
CUMC pediatric neurology clinic, were seeded in culture ﬂasks, allowed to grow
in M-106 medium (Life Technologies, Carlsbad, CA, USA) for B48 h
(B80% conﬂuent) and then transferred to 6-well plates for transfection. Plasmid
was delivered to the cells by electroporation using the Nucleofector kit (Lonza,
Cologne, Germany). Astrocyte cultures for measurements of glycolytic ﬂux were
obtained from PND3 pups generated from crosses between Glut1 þ / þ and
Glut1 þ /  mice. Cerebral cortices were removed free of meninges, cut into small
pieces, and enzymatically dissociated for 30 min in complete PBS medium without
MgCl2 and CaCl2 (GIBCO-Invitrogen), 0.4 mg ml  1 papain (Roche), and then
mechanically dissociated, in the presence of DNase (Roche), by using glass pipettes
of different pore size. Dissociated cells were collected by centrifugation
(1,200g, 5 min). All cells used here were mycoplasma free.
Glucose uptake assay. Glucose uptake assays in the transfected cells and relevant
controls were essentially carried out as reported by us in a prior study41. Brieﬂy,
B48 h after transfection, the cells were incubated for 2 h in glucose-free DMEM,
then washed twice in pre-warmed (37 °C) PBS and further incubated in the PBS for
15 min to achieve a zero-trans condition. Glucose uptake was initiated with a 500 ml
solution containing a mix of 14C 2-DOG and unlabelled 2-DOG (Perkin Elmer,
Waltham, MA, USA). Baseline glucose transport was assessed in parallel by
subjecting one set of cells to 25 mM cytochalasin B (Sigma, St. Louis, MO, USA).
The uptake reaction was terminated after a minute with stop solution
(HgCl2 þ phloretin), the radioactive incubation medium discarded and the cells
washed three times in rapid succession with 1 ml each of ice-cold stop solution.
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Ice-cold ethanol (1 ml, 100%) was then added to the culture plates and the
cells lysed in the solution for 30 min. The entire lysate and 5 mls of the Hionic
Fluor cocktail (Perkin Elmer, Waltham, MA, USA) was then placed in
a scintillation vial and 14C 2-DOG inﬂux quantiﬁed in a scintillation counter
(Tri-carb 2300 TR counter, Packard Biosciences, Meridien, CT). To correct for
possible variations in cell number, cell pellets from the above experiment were
digested (0.1N NaOH, 0.1% Triton X-100) and protein concentrations in 50 ml
aliquots assessed using the Bio-Rad protein assay kit (Bio-Rad Labs, Hercules,
CA, USA). Glucose uptake was expressed relative to total cell protein.
Phenotypic evaluations and CSF/blood glucose measurements. Glut1 DS mice
were initially created at Columbia University and maintained on a 129/SvJ genetic
background. Mutants for this project were generated by breeding mutant male
mice with WT females, and identiﬁed by PCR as previously described11. For the
behavioural studies GraphPad Prism was used to determine sample sizes to detect
differences of at least two standard deviations with a power of 80% (Po0.05). Mice
were not randomized, but as mutants do not exhibit an overt disease phenotype, it
was possible to blind the investigator to the particular cohort being assessed. Motor
performance in the different cohorts of mice was evaluated by rotarod analysis
and/or a vertical pole test. To administer the rotarod test, mice were subjected
to a training period of 5 min on an accelerating rotarod (Ugo Basile Inc., Italy)
three times a day for four consecutive days. Measurements were recorded on the
ﬁfth day at a setting of 25 r.p.m. Duration of time on the rotating rod was recorded
and the experiment terminated if a mouse surpassed 1,000 s. The vertical pole test
employed a protocol initially described by Matsuura et al.58 and reﬁned by us
in a study to examine a mouse model of spinal muscular atrophy57. Brieﬂy, mice
were placed in the centre of a vertically positioned metal pole (60 cm long, 1 cm
diameter) covered with a mesh tape, with their snouts oriented toward the ceiling.
Motor performance was measured by the latency to turn around to descend the
pole. To assess brain and body size, and investigate CSF/serum glucose levels, mice
were ﬁrst subjected to an overnight fasting period. Subsequently they were weighed,
blood collected from the tail vein, CSF extracted from the cisterna magna as
detailed by us in a prior study11 and the brain removed and weighed. Glucose
concentrations in the CSF and blood were assessed on disposable strips using
a Contour Next EZ glucose meter (Bayer Corp., NJ, USA) and reﬂect levels in freely
moving animals. Except for the determination of brain and body weights where
results presented are from male mice alone, experiments described in this study
included animals of either gender. To preclude strain background effects, littermate
controls were used in all experiments. Additionally, all experiments were
conducted in accordance with the protocols described in the NIH Guide for the
Care and Use of Animals and were approved by the Columbia University
Institutional Laboratory Animal Care and Use Committees.
Virus production and administration. Recombinant virus was produced as
described below (also see ref. 59). Murine or human Glut1 cDNAs were initially
inserted into a rAAV plasmid consisting of the vector genome, a CMV-enhanced
chicken-b-actin promoter and AAV2 ITRs ﬂanking the expression cassette. To
generate virus, the plasmid carrying the mGlut1 cassette was co-transfected into
HEK 293 cells with a packaging plasmid and an adenovirus helper plasmid. The
packaging plasmid expresses AAV2 regulatory proteins and AAV9 capsid proteins.
The regulatory proteins excise the recombinant genome from the rAAV vector
plasmid, replicate the genome, and package it into AAV virions. Adenovirus
serotype 5 E1, E2a and E4 proteins, and VA I and II RNAs expressed from the
adenovirus helper plasmid provide helper functions essential for rAAV rescue,
replication, and packaging. The packaged, recombinant viral particles were then
puriﬁed by a CsCl gradient sedimentation method, desalted by dialysis and
subjected to a quality control analysis as detailed elsewhere59.
Delivery of the AAV9-Glut1 vector (4.2  1011 GC in 35 ml) into PND3 mice
was accomplished through the retro-orbital sinus as reported60. Two week old mice
were similarly administered virus (1.2  1012 GC in 100 ml) after rendering them
unconscious with isoﬂurane. In contrast, adult mice were administered virus
(4  1012 GC in 400 ml) through the tail vein. To do so, the mice were ﬁrst
restrained, the tail sterilized with alcohol and the tissue warmed under a brooder
lamp for 5 min to dilate the tail vein and facilitate delivery of the virus. To deliver
virus (3  1011 GC) into the intra-cerebral ventricles of mice we followed
a protocol described by Glascock and colleagues61.
Quantitative PCR. Glut1 and BBB signature gene transcript levels were determined by QPCR. RNA was extracted from the relevant tissue using Trizol
(Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions and 2 mg reverse transcribed following treatment with DNAse. QPCRs were
carried out on a Realplex4 Mastercycler (Eppendorf, Germany) using Maxima
SYBR green (Thermoﬁsher Scientiﬁc, Waltham, MA, USA). All samples were run
in triplicate and relative concentrations calculated using the ddCT method and by
normalizing to b-actin (for Glut1 expression) or to GAPDH (for the BBB signature
genes). PCR primers are indicated in the table (Table 1) below.
Western blotting. Glut1 protein levels in the various cohorts of mice
were assessed by western blot analysis using standard techniques described
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Table 1 | PCR primers utilized to examine levels of BBB
signature genes or transcripts altered in Glut1 DS.
Gene
Glut1 F
Glut1 R
Cldn3 F
Cldn3 R
Cldn5 F
Cldn5 R
Cldn12 F
Cldn12 R
Cdh5 F
Cdh5 R
Abcb1b F
Abcb1b R
Abcg2 F
Abcg2 R
Plvap F
Plvap R
b-actin F
b-actin R
Gapdh F
Gapdh R
Vegfr2 F
Vegfr2 R

Primer sequence
50 CTT GCT TGT AGA GTG ACG ATC 30
50 CAG TGA TCC GAG CAC TGC TC 30
50 GAT GGG AGC TGG GTT GTA CG 30
50 GAG GAT CTT GGT GGG TGC AT 30
50 GTT AAG GCA CGG GTA GCA CT 30
50 TAC TTC TGT GAC ACC GGC AC 30
50 GTC CTG TCC TTC CTG TGT GG 30
50 TGA ATG TGA TCA GCC GCA GT 30
50 ATT GGC CTG TGT TTT CGC AC 30
50 CAC AGT GGG GTC ATC TGC AT 30
50 GG GAG ATC CTC ACC AAG CG 30
50 CCC ATC GCC CCT TA ACA CT 30
50 TGG ACT CAA GCA CAG CGA AT 30
50 CGG AAG CCA GTA AGG TGA GG 30
50 CGT CAA GGC CAA GTC GCT 30
50 CAG CAG GGT TGA CTA CAG GG 30
50 TGT TAC CAA CTG GGA CGA CA 30
50 GGG GTG TTG AAG GTC TCA AA 30
50 CGA CTT CAA CAG CAA CTC CCA CTC TTC C 30
50 TGG GTG GTC CAG GGT TTC TTA CTC CTT 30
50 CTA GCT GTC GCT CTG TGG TT 30
50 CTG TCC CCT GCA AGT AAT CTG A 30

elsewhere11,62. Brieﬂy, cells or tissues were lysed in lysis buffer containing protease
inhibitors (Complete Protease Inhibitor Cocktail tablets and pepstatin each from
Roche, Indianapolis, IA, USA) and 50 mg of total protein resolved by gradient
SDS-PAGE (Bio-Rad Labs, Hercules, CA, USA). Glut1 rabbit polyclonal
(1:5,000; Millipore; #CBL242) and SMN mouse monoclonal (1:5000; BD
Biosciences; #610640) antibodies were probed respectively with HRP-linked
donkey anti-rabbit (Santa Cruz Biotechnology; #sc2317) and sheep anti-mouse
(GE Healthcare) secondary antibodies each diluted 1:5000 and visualized on
an ImageQuant LAS 4000 machine (GE Healthcare; #NA-931) using the
ECL Detection Kit (RPN 2109; GE Healthcare). Band intensities were determined
using ImageJ software (NIH). Western blots of Vegfr2 were carried out using
a rabbit monoclonal antibody (1:2,000; Thermoﬁsher; #B.309.4) and a mouse
monoclonal antibody against actin (1:5000; Sigma; #A5441). Note: western blot
images have been cropped for presentation. Full-sized membrane strips probed
with the respective antibodies are presented in Supplementary Fig. 10.
Blood chemistry. Mice were euthanized with CO2 gas and B700 ml of blood
aspirated from the right ventricle using a 21-Gauge needle. The blood was allowed
to clot for an hour in Microtainer Serum Separator Tubes (BD Biosciences, San
Jose, CA, USA) and then centrifuged at 2,000 r.p.m. for 15 min. The upper (serum)
phase was collected and albumin and IgG levels assessed at the Charles River
Laboratory using ELISA assay kits (Albumin kit: #E90AL; IgG kit: #E90G,
Immunology Consultants Laboratory, Portland, OR, USA).
Histochemistry. The cerebral microvasculature was assessed in 50 mm thick
coronal sections using an antibody against Glut1 or labelled lectin. Details are
supplied in the supplemental methods section. Capillary density and complexity in
the various brain regions examined involved quantifying individual and aggregate
length of vessels o6 mm in diameter in a 240 mm2 area or 0.003 mm3 volume.
Three such areas, non-adjacent to one another, in each animal were examined.
Hematoxylin/eosin staining experiments were performed on parafﬁn-embedded
8 mm coronal sections (brain), 4 mm longitudinal sections (liver, heart, kidney
and muscle) or 4 mm transverse sections (intestines) and imaged on an Eclipse
80i Nikon microscope (Nikon, Japan).
BBB integrity. To examine the integrity of the Glut1 deﬁcient BBB, BSA
conjugated to Alexa Fluor-594 (1 mg per 20 g; Life Technologies), FITC-labelled
goat anti-human IgG (150 mg/20 g; Jackson Immunoresearch) or TMR-biocytin
(1% in PBS; Thermoﬁsher) was injected into the tail veins of mice. Perfused
(4% PFA) brains from the mice were harvested 16 h (BSA, IgG) or 30 min
(TMR-bioctyin) post-injection and 50 mm coronal sections cut on a vibratome. The
tissue was then either stained with ﬂuorescently labelled lectin or an anti-Glut1
antibody, and the microvasculature imaged on a confocal Leica TCS SP5 II
microscope. To disrupt the BBB, mice were exposed to kainic acid (15 mg kg  1,
I.P.) 24 h before injecting them with labelled bioctyin, BSA or IgG.

Cerebral microvasculature. To examine the cerebral microvasculature, whole
brains were extracted following transcardial perfusion with 1  PBS and 4% PFA.
The tissue was post-ﬁxed overnight in 4% PFA and coronal sections (50 mm) cut on
a vibratome the following day. The sections were incubated (1 h, RT) in blocking
solution (3% BSA, 0.5% Triton X-100 in PBS) before further incubating them at
4 °C overnight (with a rabbit anti-eGFP antibody, 1:1,000, Life Technologies) or for
48 h (with a rabbit anti-Glut1 antibody, 1:1,000, Millipore). They were then washed
three times (15 min each) with 1X PBS and an appropriate ﬂuorescently labelled
secondary antibody diluted 1:1,000 in blocking solution allowed to bind the
primary antibody overnight at 4 °C. Following a second set of washing steps, the
slides were mounted (Vectashield, Vector Labs, Burlington, VT, USA) on slides,
overlaid with a coverslip and imaged on a Leica TCS SP5 II confocal microscope.
Images presented in the manuscript are reconstructions of three dimensional
z-stacks. Lectin staining was performed in a similar fashion following treatment
of the tissue sections with ﬂuorescein-labelled Lycopersicon esculentum lectin
(Vector Labs).

In vivo, two-photon microscopy. To image the cerebral microvasculature in live
animals, we followed a protocol previously described by McCaslin et al.42 Eight
week old mice, administered AAV9-Glut1 at PND3, and relevant controls were
anesthetized (1,500 mg kg  1 urethane and 500 mg kg  1 glycopyrrolate,
administered intraperitoneally). Next, a craniotomy on the right hemisphere
between bregma and lamda was performed, following which ﬂuoresceinconjugated dextran (2,000 kDa, 0.1 ml from 25 mg ml  1) injected into the tail vein
to enable visualization of the capillaries. Images were acquired using a home-built
two-photon laser scanning microscope63,64 equipped with a 20  , 0.95 NA
objective lens (XLUMPLanFl, Olympus). Stacks of angiograms (B510  510 mm)
were constructed beginning at the cortical surface down to a depth of B500 mm.
Images were acquired every 2 mm in the z axis. Microvascular length was quantiﬁed
by modifying an image processing pipeline previously described65. Image analysis
was performed using ImageJ and MATLAB. Brieﬂy, three sub-regions
(510  510  20 mm) at depths of 200, 300 and 400 mm were selected from the
stack. The mean image of the sub-region was ﬁrst pre-processed with a tubeness
ﬁlter to enhance the features of the vessels. Then, an automatic intensity
thresholding was applied to segment the vessels. Capillary diameter was further
determined by skeletonization and Euclidean distance map. Only blood vessel
segments with diameters of o6 mm were included in the ﬁnal result.

Small animal FDG-PET and EEG analysis. Wild-type (n ¼ 11), Glut1 DS (n ¼ 12)
and AAV9-Glut1 (n ¼ 4) animals were fasted for approximately 9–12 h before
imaging. Mice were placed in an induction chamber containing B2% isoﬂurane/
oxygen and then secured to a custom 4-mouse bed for placement of tail vein
catheters. Anesthesia (B1% isoﬂurane/oxygen) and body temperature were
maintained during the imaging procedures. The mice underwent dynamic
small animal PET imaging from 0 to 60 min after intravenous tail injection of
210  235 mCi (7.4  8.7 MBq) of [18F]FDG using an INVEON PET/CT system
(Siemens Medical Solutions). Computed tomography (CT) images were acquired
with the INVEON system on all mice. The PET data was analysed by manually
drawing 3D regions of interest over the entire brain using the Inveon Research
Workplace software package (Siemens) and uptake expressed as average standardized uptake values. EEG monitoring and analysis were performed using methods
detailed by us in a prior study11.

Glycolytic ﬂux and mitochondrial respiration studies. Mutant or WT cells,
derived as described in supplemental methods, were directly seeded on the
XF 24-plate at a density of 6  104 cells per well in DMEM-F12 (1:1) medium
supplemented with 10% fetal bovine serum (FBS) and 2 mM Glutamine. Media was
replaced every 3–4 days. After 2 weeks in vitro cells were equilibrated with
bicarbonate-free DMEM medium (without pyruvate, lactate, glucose, glutamine;
Seahorse bioscience) supplemented with 2.5 mM glucose. The OCR and ECAR
was measured using a Seahorse XFe24 Extracellular Flux Analyzer
(Seahorse Bioscience)34. After a baseline measurement, mitochondrial function and
glycolytic ﬂux was determined as previously described66. Oxygen consumption and
glycolytic rates in astrocytes were determined through sequential addition of 6 mM
oligomycin, 0.5 mM 2,4-dinitrophenol, and 1 mM antimycin per 1 mM rotenone.
After the experiment, protein concentration was determined for each well and
OCR and ECAR values were normalized by mg. protein.

Statistics. The unpaired 2-tailed Student’s t-test with Welch’s correction or oneway ANOVA followed by Tukey’s post hoc comparison, where indicated, was used
to compare means for statistical differences. To determine if there was a signiﬁcant
alteration in protein concentrations in the CSF of Glut1 DS patients, a one-sample
t-test was used and a comparison made to the mean value obtained from Biou
et al.29 Data in the manuscript are represented as mean±s.e.m. unless otherwise
indicated. Po0.05 was considered signiﬁcant. Statistical analyses were performed
with GraphPad Prism v6.0 (GraphPad Software).
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Data availability. The authors declare that all data supporting the ﬁndings of this
study are contained within the article and its Supplementary Information Files or
available from the authors upon request.
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43. Görs, S., Kucia, M., Langhammer, M., Junghans, P. & Metges, C. C. Technical
note: milk composition in mice--methodological aspects and effects of mouse
strain and lactation day. J. Dairy Sci. 92, 632–637 (2009).
44. Butchbach, M. E., Singh, J., Gurney, M. E. & Burghes, A. H. The effect of diet
on the protective action of D156844 observed in spinal muscular atrophy mice.
Exp. Neurol. 256, 1–6 (2014).
45. Pellerin, L., Pellegri, G., Martin, J. L. & Magistretti, P. J. Expression of
monocarboxylate transporter mRNAs in mouse brain: support for a distinct
role of lactate as an energy substrate for the neonatal vs. adult brain. Proc. Natl
Acad. Sci. USA 95, 3990–3995 (1998).
46. Vannucci, S. J. & Simpson, I. A. Developmental switch in brain nutrient
transporter expression in the rat. Am. J. Physiol. Endocrinol. Metab. 285,
E1127–E1134 (2003).
47. Simpson, I. A., Vannucci, S. J. & Maher, F. Glucose transporters in mammalian
brain. Biochem. Soc. Trans. 22, 671–675 (1994).
48. Mancuso, M. R., Kuhnert, F. & Kuo, C. J. Developmental angiogenesis of the
central nervous system. Lymphat. Res. Biol. 6, 173–180 (2008).
49. Zheng, P. P. et al. Glut1/SLC2A1 is crucial for the development of the bloodbrain barrier in vivo. Ann. Neurol. 68, 835–844 (2010).
50. Winkler, E. A. et al. GLUT1 reductions exacerbate Alzheimer’s disease
vasculo-neuronal dysfunction and degeneration. Nat. Neurosci. 18, 521–530
(2015).
51. Esraghi, M., McFall, E., Gibeault, S. & Kothary, R. Effect of genetic background
on the phenotype of the Smn2B/  mouse model of spinal muscular atrophy.
Hum. Mol. Genet, doi: 10.1093/hmg/ddw278 (2016).
52. Schauwecker, P. E. The relevance of individual genetic background and its role
in animal models of epilepsy. Epilepsy Res. 97, 1–11 (2011).
53. Tung, J. J., Tattersall, I. W. & Kitajewski, J. Tips, stalks, tubes: notch-mediated
cell fate determination and mechanisms of tubulogenesis during angiogenesis.
Cold Spring Harb. Perspect. Med. 2, a006601 (2012).
54. Harb, R., Whiteus, C., Freitas, C. & Grutzendler, J. In vivo imaging of cerebral
microvascular plasticity from birth to death. J. Cereb. Blood Flow Metab. 33,
146–156 (2013).
55. Xu, Y. et al. Endothelial PFKFB3 plays a critical role in angiogenesis.
Arterioscler. Thromb. Vasc. Biol. 34, 1231–1239 (2014).
56. Kariya, S. et al. Reduced SMN protein impairs maturation of the
neuromuscular junctions in mouse models of spinal muscular atrophy. Hum.
Mol. Genet. 17, 2552–2569 (2008).
57. Kariya, S. et al. Requirement of enhanced survival motoneuron protein
imposed during neuromuscular junction maturation. J. Clin. Invest. 124,
785–800 (2014).

NATURE COMMUNICATIONS | 8:14152 | DOI: 10.1038/ncomms14152 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14152

58. Matsuura, K., Kabuto, H., Makino, H. & Ogawa, N. Pole test is a useful method
for evaluating the mouse movement disorder caused by striatal dopamine
depletion. J. Neurosci. Methods 73, 45–48 (1997).
59. Gao, G. P. & Sena-Esteves, M. in Molecular Cloning, Vol 2: A Laboratory
Manual. (eds Green, M. R. & Sambrook, J.) 1209–1313 (Cold Spring Harbor
Laboratory Press, New York, 2012).
60. Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M. & Hoogstraten-Miller, S.
Retro-orbital injections in mice. Lab Anim. 40, 155–160 (2011).
61. Glascock, J. J. et al. Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice. J. Vis. Exp. 56,
2968 (2011).
62. Monani, U. R. et al. The human centromeric survival motor neuron gene
(SMN2) rescues embryonic lethality in Smn(-/-) mice and results in
a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333–339
ð2000Þ:
63. Galwaduge, P. T., Kim, S. H., Grosberg, L. E. & Hillman, E. M. Simple
wavefront correction framework for two-photon microscopy of in-vivo brain.
Biomed. Opt. Express 6, 2997–3013 (2015).
64. Cebulla, J., Kim, E., Rhie, K., Zhang, J. & Pathak, A. P. Multiscale and multimodality visualization of angiogenesis in a human breast cancer model.
Angiogenesis 17, 695–709 (2014).
65. Pons, R., Collins, A., Rotstein, M., Engelstad, K. & De Vivo, D. C. The spectrum
of movement disorders in Glut-1 deﬁciency. Mov. Disord. 25, 275–281
ð2010Þ:
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